(Q53609113)

English

Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

hydroxychloroquine

1 reference

based on heuristic

inferred from title

myocardial infarction

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

author name string

Otto Hartman

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Petri T Kovanen

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Jukka Lehtonen

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Kari K Eklund

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

publication date

1 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

European heart journal. Cardiovascular pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

92-97

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Mechanisms of acute coronary syndromes and their implications for therapy

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Toll-like Receptors in the Vascular System: Sensing the Dangers Within

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Cytokines in atherosclerosis: pathogenic and regulatory pathways

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Pleiotropic effects of statins. - Basic research and clinical perspectives -.

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Third universal definition of myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Cohort Profile: the Corogene study

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials

1 reference

https://api.crossref.org/works/10.1093%2FEHJCVP%2FPVW035

21 January 2018

Identifiers

10.1093/EHJCVP/PVW035

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/28025216

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53609113&oldid=1231627142"